Cardiovascular and cerebrovascular events in the randomized, controlled Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT)
about
Aspirin, steroidal and non-steroidal anti-inflammatory drugs for the treatment of Alzheimer's diseaseNon-steroidal anti-inflammatory drugs as disease-modifying agents for Parkinson's disease: evidence from observational studiesA turbulent decade for NSAIDs: update on current concepts of classification, epidemiology, comparative efficacy, and toxicityNSAIDs and Cardiovascular Diseases: Role of Reactive Oxygen SpeciesImpairment of aspirin antiplatelet effects by non-opioid analgesic medicationChemoprevention in familial adenomatous polyposisElevated ratio of urinary metabolites of thromboxane and prostacyclin is associated with adverse cardiovascular events in ADAPTNSAID use selectively increases the risk of non-fatal myocardial infarction: a systematic review of randomised trials and observational studiesClinical Pharmacology and Cardiovascular Safety of NaproxenLong-term drug prevention trials.Safe prescribing of non-steroidal anti-inflammatory drugs in patients with osteoarthritis--an expert consensus addressing benefits as well as gastrointestinal and cardiovascular risksThe amyloid cascade-inflammatory hypothesis of Alzheimer disease: implications for therapy.Maintaining confidentiality of interim data to enhance trial integrity and credibility.ADAPT: the wrong way to stop a clinical trial.Cholesterol and cognitive performance in normal controls and the influence of elective statin use after conversion to mild cognitive impairment: results in a clinical trial cohort.Ethical issues with the disclosure of surgical trial short-term data.Alzheimer's Disease Anti-inflammatory Prevention Trial: design, methods, and baseline resultsThe Cache County Study on Memory in Aging: factors affecting risk of Alzheimer's disease and its progression after onsetTracking neuroinflammation in Alzheimer's disease: the role of positron emission tomography imaging.Celecoxib does not attenuate the antiplatelet effects of aspirin and clopidogrel in healthy volunteers.Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib.Nonsteroidal anti-inflammatory drugs and cardiovascular outcomes in women: results from the women's health initiativeDifferences in medication use in the Alzheimer's disease neuroimaging initiative: analysis of baseline characteristicsCardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis.Individual NSAIDs and upper gastrointestinal complications: a systematic review and meta-analysis of observational studies (the SOS project)The transitioning from trials to extended follow-up studies.Relative cardiovascular and gastrointestinal safety of non-selective non-steroidal anti-inflammatory drugs versus cyclo-oxygenase-2 inhibitors: implications for clinical practice.Epidemiology of Alzheimer's disease: occurrence, determinants, and strategies toward intervention.Aspirin and familial adenomatous polyposis: coming full circleExtended results of the Alzheimer's disease anti-inflammatory prevention trial.Coxibs and other nonsteroidal anti-inflammatory drugs in animal models of cancer chemoprevention.Chemical Biology, Molecular Mechanism and Clinical Perspective of γ-Secretase Modulators in Alzheimer's DiseaseRole of APOE and Age at Enrollment in the Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT).Non-steroidal anti-inflammatory drug-induced cardiovascular adverse events: a meta-analysis.Nonsteroidal anti-inflammatory drugs and cardiovascular safety - translating pharmacological data into clinical readouts.Anti-inflammatory and immune therapy for Alzheimer's disease: current status and future directions.Cognitive and cerebral metabolic effects of celecoxib versus placebo in people with age-related memory loss: randomized controlled study.Cytochrome P450 2C9 variants influence response to celecoxib for prevention of colorectal adenoma.Non-steroidal anti-inflammatory drugs and cardiac failure: meta-analyses of observational studies and randomised controlled trials.Results of a follow-up study to the randomized Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT).
P2860
Q24203739-D5C3833B-993C-4E56-B2D3-9C6438B94DA9Q24235107-AAE4D084-CB5D-4719-8E70-8FEF46581B53Q24615651-4230CA5C-1B44-4327-9C23-03E0C4DBA6E1Q26784322-6A840EA0-B7D7-4A42-9459-E7EAE4AD4E19Q26801633-FCDD5D78-157B-4DF8-A68F-EB50E2EBE217Q27023845-1BD3F07B-79FD-4410-8D3E-CED69E2967CFQ28472972-70B932BE-9AEB-4A13-87A4-01629CC58745Q28742977-3552C390-582D-4BC3-94D0-38DA9D581543Q30360728-32950468-8C77-4CC0-968C-271C7AF001DAQ30368543-99C397E5-CD38-4124-AE32-607829575AF4Q30629677-AF94EDB5-1943-49DF-800C-DCA6BDDEFF20Q30668465-C0ABC4B3-4B72-4827-A922-DA35532EDA6DQ31151039-70B94B76-18F1-4142-991B-F0ED29BAE99BQ33263888-1DF28B63-9EAF-4E11-9C8B-9883FD780292Q33808792-C57AD83D-336B-4DF3-B86F-06F38769770BQ33826771-E7C75978-AE7E-4D4A-8E61-86F6F4319556Q33836869-FC90AB7D-6076-4041-A953-5827765B6F7CQ33873941-348A9D8D-F980-4927-8CAD-064284C4E641Q33904501-E8DE12AD-795D-4F80-BCB9-C3D405AD8A39Q34021188-D447AC64-1FF6-4FB4-A8DB-EF30F64A3BB7Q34077849-A60D3F16-DF4C-4B33-9B18-D3C9976FA27AQ34117657-0A9A9386-44C0-4CB8-BC3C-00A7B8C6C6E5Q34181037-EC93ADFF-1471-46C2-9930-D9C9A550FC2DQ34247727-49E798A7-937F-4FA9-A95B-D7519946C743Q34310573-6554B704-227B-419E-BE23-0D7B471EA539Q34498537-65D0568A-8970-4413-91E8-FD685AA9256EQ34556831-A268E0A8-192A-49E0-896C-CE4DB5377700Q34991223-D7904599-C7D2-4837-AD5D-3ABEDC19A570Q34992425-36862DB9-C9EC-4E3C-9366-9BA989DED28AQ35146385-56F65B57-F6E4-413B-81C3-19830A23D795Q35529238-B1E09860-05E5-436D-9444-B197099E3F74Q36081889-53595237-B05F-453B-91E1-3AE44FB2E763Q36213829-EB130571-9CEE-4105-B5EC-2DAB410C4A7CQ36233306-92367745-D095-4F3C-9BE6-BDA1C0385622Q36388949-0E671153-0068-4BD3-9D70-9B75EE27F9FBQ37101754-8609D72E-0FA9-411A-8F49-6740459F3287Q37219776-07D18270-8A54-49BC-9E57-87B745D673A5Q37219846-C02C5A9F-081A-42DD-A472-7EC258E1DC04Q37257464-B9C18054-FE47-43AE-B22C-703E6785C80EQ37297193-459CD2B9-5888-4BE8-AD09-E0DC19DA9348
P2860
Cardiovascular and cerebrovascular events in the randomized, controlled Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT)
description
2006 nî lūn-bûn
@nan
2006 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Cardiovascular and cerebrovasc ...... atory Prevention Trial (ADAPT)
@ast
Cardiovascular and cerebrovasc ...... atory Prevention Trial (ADAPT)
@en
Cardiovascular and cerebrovasc ...... atory Prevention Trial (ADAPT)
@nl
type
label
Cardiovascular and cerebrovasc ...... atory Prevention Trial (ADAPT)
@ast
Cardiovascular and cerebrovasc ...... atory Prevention Trial (ADAPT)
@en
Cardiovascular and cerebrovasc ...... atory Prevention Trial (ADAPT)
@nl
prefLabel
Cardiovascular and cerebrovasc ...... atory Prevention Trial (ADAPT)
@ast
Cardiovascular and cerebrovasc ...... atory Prevention Trial (ADAPT)
@en
Cardiovascular and cerebrovasc ...... atory Prevention Trial (ADAPT)
@nl
P2860
P921
P1433
P1476
Cardiovascular and cerebrovasc ...... atory Prevention Trial (ADAPT)
@en
P2860
P356
10.1371/JOURNAL.PCTR.0010033
P407
P577
2006-11-17T00:00:00Z